Citations

Clear

22 citation(s) found for "Meyer, Christian".

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Kim, Aerang, Ballman, K., Wolters, Pamela L. , Heise, Rachel S. , Shern, J., Sundby, R. Taylor , Lindenberg, Liza , Lee, Min-Jung , Rastogi, Shraddha , Shahsavari, Shirin, Tine, Brian A. Van, Meyer, Christian F. , Pratilas, Christine A. , Collins, Natalie B. , Coyne, Geraldine O'Sullivan, Chen, Alice P. , Dombi, Eva, Shrestha, Roshan L., Cichowski, Karen M. , Widemann, B. C., Ballman, Karla V. , Kim, AeRang , Cichowski, Karen , Shern, Jack F. , Sundby, R. Taylor , Kim, AeRang , Ballman, Karla , Shern, Jack F , Sato, Nahoko , Shahsavari, Shirin , Hirbe, Angela C , Van Tine, Brian A , Meyer, Christian , Pratilas, Christine A , Collins, Natalie B , O'Sullivan Coyne, Geraldine , Chen, Alice P , Dombi, Eva , Shrestha, Roshan L , Gross, Andrea M , Reinke, Denise , Widemann, Brigitte C , Heise, Rachel , Wolters, Pamela L. , Hirbe, Angela C. , Tine, Brian A. Van , Dombi, Eva , Gross, Andrea M. , Reinke, Denise K.

Mayo Clinic

Clinical Cancer Research | January 8, 2026 | Volume: 32 | Issue: 6 | Pages: 1068-1077

10.1158/1078-0432.ccr-25-2887 | PMID 41504652 Get It

Abstract Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025
Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa, Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pappo, Alberto S., Pollack, Seth M., Poppe, Matthew, Riedel, Richard F., Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat, Pappo, Alberto S. , Riedel, Richard F. , Riedel, Richard F , Mehren, Margaret von, Kane, John M., Armstrong, Samantha A., Balach, Tessa, Bishop, Andrew J., Buehler, Darya, Carr-Ascher, Janai, Choy, Edwin, Cipriano, Cara, Connolly, Mary, Dann, Amanda, Davis, Elizabeth J., Dry, Sarah, Eulo, Vanessa Anne , Ganjoo, Kristen N., Gonzalez, Ricardo J., Viveiros, Pedro A. Hermida De, Hitchcock, Ying J., Kim, Edward, Lefler, Daniel, Liebner, David, McCarter, Martin, McGarry, Sean V., Mesko, Nathan W., Meyer, Christian, Motamedi, Kambiz, Movva, Sujana, Pollack, Seth M., Poppe, Matthew, Robinson, Steven, Schuetze, Scott M., Sicklick, Jason K., Tseng, William W., Weiss, Mia C., Zimel, Melissa, Hang, Lisa E., Bergman, Mary Anne, Diwan, Zeenat

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 17, 2025 | Volume: 23 | Issue: 12 | Pages: 498-506

10.6004/jnccn.2025.0058 | PMID 41671462 Get It

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
Clinical neurocardiology: defining the value of neuroscience‐based cardiovascular therapeutics – 2024 update
Aksu, Tolga , Arora, Rishi , Chen, Peng‐Sheng , Fudim, Marat , Herring, Neil , Po, Sunny S. , Stavrakis, Stavros , Somers, Virend K. , Tan, Alex Y. , Valderrábano, Miguel , Shivkumar, Kalyanam , Shivkumar, Kalyanam , Ajijola, Olujimi A. , Biaggioni, Italo , Ferrari, Gaetano Maria De , Dusi, Veronica , Goldberger, Jeffrey J , Green, Alexander L. , Khalsa, Sahib S. , Kumar, Rajesh , Lakatta, Edward G. , Mehra, Reena , Meyer, Christian , Somers, Virend K.

Mayo Clinic

The Journal of Physiology | March 12, 2025 | Volume: 603 | Issue: 7 | Pages: 1781-1839

10.1113/jp284741 | PMID 40056025 Get It

AbstractThe intricate role of the autonomic nervous system (ANS) in regulating cardiac physiology has long been recognized. Aberrant function of the ANS is central to the pathophysiology of cardiovascular diseases. It stands to reason, therefore, that neuroscience‐based cardiovascular therapeutics hold great promise in the treatment of cardiovascular diseases in humans. A decade after the inaugural edition, this White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology and pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases. image
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Naing, Aung , Javle, Milind , Bajor, David L. , Shields, Anthony F. , Chawla, Sant P. , Safran, H., Powderly, John D. , D’Amato, Gina Z. , Meyer, Christian F. , Tang, Xiongwen , Yao, Sheng , Keegan, Patricia , Keegan, Patricia , Mahipal, Amit , Wang, Judy , Bauer, Todd Michael , Elias, Anthony , Davis, Elizabeth J.

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | January 14, 2025 | Volume: 8 | Issue: 1 | Pages: 71-81

10.36401/jipo-24-8 | PMID 39816916 Get It

Introduction This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti–programmed cell death-1 inhibitor) in patients with advanced malignancies. Methods Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B. The primary endpoint was safety assessment. Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) as assessed by the investigators according to Response Evaluation Criteria in Solid Tumors (version 1.1) and overall survival (OS). Results In part B, 166 patients, including the 42 patients with CCA, were enrolled and received toripalimab. Among the 166 patients, treatment-emergent adverse events (TEAEs) of any grade occurred in 158 (95.2%) patients, and 97 (58.4%) patients experienced TEAEs of Grade 3 or greater. The most common TEAE was fatigue (42.2%). Seven (4.2%) patients experienced TEAEs with a fatal outcome, none of which were identified by investigators as related to toripalimab. Investigator-assessed immune-related adverse events (irAE) of Grade 3 or higher occurred in 7 (4.2%) patients. In the CCA cohort, with the median follow-up of 4.4 months, the ORR and DCR were 4.8% (95% CI: 0.58, 16.16) and 40.5% (95% CI: 25.63, 56.72), respectively; median DoR was 7.8 (range 4.4+ to 7.8) months; median PFS was 2.1 (95% CI: 1.91, 3.88) months; median OS was not estimable. Conclusions Toripalimab had manageable side effects in patients with refractory cholangiocarcinoma and exhibited preliminary evidence of anti-tumor activity. However, further information regarding biomarkers is needed. ClinicalTrials.gov ID: NCT03474640
Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics
Sundby, R. Taylor , Szymanski, Jeffrey J. , Pan, Alexander , Jones, Paul A. , Mahmood, Sana , Reid, Olivia H. , Srihari, Divya , Armstrong, Amy E. , Chamberlain, Stacey , Burgic, Sanita , Weekley, Kara , Murray, Béga , Patel, S. G. , Qaium, Faridi , Lucas, Andrea N. , Fagan, Margaret , Dufek, Anne , Meyer, Christian F. , Collins, Natalie B. , Pratilas, Christine A. , Gross, Andrea M. , Widemann, Brigitte C. , Chaudhuri, Aadel A. , Pan, Alexander C , Mahmood, Sana Z , Patel, Sneh , Dombi, Eva , Gross, Andrea M , Kim, AeRang , Chrisinger, John S A , Dehner, Carina A , Widemann, Brigitte C , Hirbe, Angela C , Chaudhuri, Aadel A , Shern, Jack F , Sundby, R. Taylor , Collins, Natalie B , Dombi, Eva , Kim, AeRang , Chrisinger, John S.A. , Dehner, Carina , Hirbe, Angela C. , Shern, Jack F.

Mayo Clinic

Clinical Cancer Research | August 2, 2024 | Volume: 30 | Issue: 19 | Pages: 4363-4376

10.1158/1078-0432.ccr-24-0797 | PMID 39093127 Get It

Abstract Purpose: Early detection of neurofibromatosis type 1 (NF1)–associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, enabling early definitive treatment and potentially averting deadly outcomes. In this study, we describe a cell-free DNA (cfDNA) fragmentomic approach that distinguishes nonmalignant, premalignant, and malignant forms of PNST in the cancer predisposition syndrome, NF1. Experimental Design: cfDNA was isolated from plasma samples of a novel cohort of 101 patients with NF1 and 21 healthy controls and underwent whole-genome sequencing. We investigated diagnosis-specific signatures of copy-number alterations with in silico size selection as well as fragment profiles. Fragmentomics were analyzed using complementary feature types: bin-wise fragment size ratios, end motifs, and fragment non-negative matrix factorization signatures. Results: The novel cohort of patients with NF1 validated that our previous cfDNA copy-number alteration–based approach identifies malignant PNST (MPNST) but cannot distinguish between benign and premalignant states. Fragmentomic methods were able to differentiate premalignant states including atypical neurofibromas (AN). Fragmentomics also adjudicated AN cases suspicious for MPNST, correctly diagnosing samples noninvasively, which could have informed clinical management. Conclusions: Novel cfDNA fragmentomic signatures distinguish AN from benign plexiform neurofibromas and MPNST, enabling more precise clinical diagnosis and management. This study pioneers the early detection of malignant and premalignant PNST in NF1 and provides a blueprint for decentralizing noninvasive cancer surveillance in hereditary cancer predisposition syndromes.
Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and th
Aksu, Tolga , Brignole, Michele , Biase, Luigi Di , Deharo, Jean‐Claude , Fanciulli, Alessandra , Fedorowski, Artur , Morillo, Carlos A. , Moya, Angel , Piotrowski, Roman , Sutton, Richard , Sheldon, Robert S. , Vaseghi, Marmar , Pachon, Jose C, Amin, Reshma , Gupta, Dhiraj, Magnano, M , Malik, Varun , Schauerte, Patrick, Shen, Win-Kuang, Acosta, Juan , Calo, Leonardo , Debruyne, Philippe , Di Biase, Luigi , Deharo, Jean Claude , Fanciulli, Alessandra , Fedorowski, Artur , Kulakowski, Piotr , Morillo, Carlos , Moya, Angel , Piotrowski, Roman , Stec, Sebastian , Sutton, Richard , van Dijk, J Gert , Wichterle, Dan , Tse, Hung-Fat , Yao, Yan , Sheldon, Robert , Vaseghi, Marmar , Pachon, Jose C , Scanavacca, Maurício , Tse, Hung‐Fat , Pachón-M, José Carlos , Scanavacca, Maurício , Meyer, Christian , Gupta, Dhiraj

Mayo Clinic

Europace | July 30, 2024 | Volume: 26 | Issue: 8 | Pages: No page available

10.1093/europace/euae206 | PMID 39082698 Get It

Abstract Cardioneuroablation has emerged as a potential alternative to cardiac pacing in selected cases with vasovagal reflex syncope, extrinsic vagally induced sinus bradycardia-arrest or atrioventricular block. The technique was first introduced decades ago, and its use has risen over the past decade. However, as with any intervention, proper patient selection and technique are a prerequisite for a safe and effective use of cardioneuroablation therapy. This document aims to review and interpret available scientific evidence and provide a summary position on the topic.
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Baird, John D. , Brooks-Asplund, Esther M. , D'Silva, Dhiren, Kong, Ronald , Mwatha, Anthony, O’Keefe, Kylie, Weetall, Marla , Spiegel, Robert J. , Van Tine, Brian A , Ingham, Matthew A , Brooks-Asplund, Esther , Schwartz, Gary K , Meyer, Christian , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | April 29, 2024 | Volume: 42 | Issue: 20 | Pages: 2404-2414

10.1200/jco.23.01684 | PMID 38684039 Get It

PURPOSE This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days. The time-to-event continual reassessment method was used to determine the RP2D on the basis of dose-limiting toxicities (DLTs) assessed during the first two 21-day treatment cycles. All explored doses of unesbulin (200 mg up to 400 mg) were in combination with DTIC. An expansion cohort was enrolled to evaluate the safety and efficacy of unesbulin at the RP2D. RESULTS Unesbulin 300 mg administered orally twice per week in combination with DTIC 1,000 mg/m2 IV once every 21 days was identified as the RP2D. On the basis of data from 27 subjects who were deemed DLT-evaluable, toxicity was higher in the unesbulin 400 mg group, with three of four subjects (75%) experiencing DLTs versus one of four subjects (25%) in the 200 mg group and three of 19 subjects (15.8%) in the 300 mg group. The most commonly reported DLTs and treatment-related grade 3 and 4 adverse events were thrombocytopenia and neutropenia. At the RP2D, seven subjects who were efficacy evaluable achieved partial response for an objective response rate of 24.1%. CONCLUSION Unesbulin 300 mg twice per week plus DTIC 1,000 mg/m2 once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.
Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
Gao, Lan , Kaushik, Diksha , Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Schwartz, Gary K. , Maliakal, Pius, Baird, John D. , Ma, Jiyuan , Barrett, Rosemary , D'Silva, Dhiren, O’Keefe, Kylie, Kong, Ronald , Van Tine, Brian A , Meyer, Christian , Schwartz, Gary K , Ingham, Matthew A

Mayo Clinic

Clinical and Translational Science | December 22, 2023 | Volume: 17 | Issue: 2 | Pages: No page available

10.1111/cts.13709 | PMID 38129988 Get It

AbstractUnesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surrogate metabolite 5‐aminoimidazole‐4‐carboxamide (AIC) in 29 patients with advanced LMS. Drug interactions between DTIC (and AIC) and unesbulin were evaluated. DTIC (1000 mg/m2) was administered to patients with LMS via 1‐h intravenous (i.v.) infusion on day 1 of every 21‐day (q21d) cycle. Unesbulin dispersible tablets were administered orally twice weekly (b.i.w.), starting on day 2 of every cycle, except for cycle 2 (C2), where unesbulin was dosed either on day 1 together with DTIC or on day 2, 1 day after DTIC administration. The PK of DTIC, AIC, and unesbulin in cycle 1 (C1) and C2 were estimated using noncompartmental analysis. DTIC and AIC were measurable immediately after the start of infusion and reached maximum plasma concentration (Cmax) immediately or shortly after end of infusion at 1.0 and 1.4 h (time to Cmax), respectively. Co‐administration of unesbulin orally at 200 mg or above with DTIC inhibited cytochrome P450 (CYP)1A2‐mediated DTIC metabolism, resulting in 66.7% reduction of AIC exposures. Such inhibition could be mitigated when unesbulin was dosed the day following DTIC infusion. Repeated unesbulin dosing demonstrated evidence of clinical CYP1A2 induction and increased AIC Cmax by 69.4% and area under concentration‐time curve to infinity by 57.9%. No meaningful difference in unesbulin PK was observed between C2 and C1. The combination therapy of 1000 mg/m2 i.v. DTIC q21d and 300 mg unesbulin b.i.w. in a staggered regimen is well‐tolerated in patients with LMS.
DDDR-28. EGFR AND SRC-MEDIATED ACTIVATION OF STAT3 DRIVES RESISTANCE TO MITOTIC INHIBITORS IN GLIOBLASTOMA, AND CAN BE REVERSED WITH FDA-APPROVED DRUGS
Kenchappa, Rajappa S., Dovas, Athanassios, Pereira, Brianna , Griffith, Jessica I. , Mohammad, Afroz S., Elmquist, William F. , Quaranta, Vito , Canoll, Peter , Rosenfeld, Steven S. , Argenziano, Michael , Meyer, Christian T. , Stopfer, Lauren E. , Banu, Matei A. , Talele, Surabhi , Zarco, Natanael , White, Forest M. , Sims, Peter A.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii105-vii105

10.1093/neuonc/noac209.393 Get It

Abstract While the allure of targeted therapies in oncology has been their high degree of specificity and potency for key tumor drivers, they have been disappointing in glioblastoma (GBM), even for drugs that are blood brain barrier permeable and CNS retained. This point is highlighted by the experience with mitotic spindle inhibitors, drugs which block the G2M transition and induce mitotic catastrophe—a phenotype characterized by cell enlargement and polyploidy that leads to apoptotic cell death. We have shown that one of these, a potent inhibitor of the mitotic kinesin Kif11 (ispinesib), is highly active against GBM tumor initiating cells and prolongs survival in murine models of this disease. However, tumors eventually progress, reflecting the development of drug resistance. Although ispinesib resistant GBM cells develop mitotic catastrophe, they become highly resistant to the apoptosis that typically follows and continue to proliferate. We find that this apoptosis resistance requires phosphorylation of the transcription factor STAT3 at two residues—Y705 and S727. Phosphorylation of Y705, mediated by SRC kinase, translocates STAT3 to the nucleus where it induces transcription of anti-apoptotic proteins. Phosphorylation at S727, mediated by EGFR, translocates STAT3 to the mitochondria where it blocks release of cytochrome c—the penultimate effector in apoptosis. Simultaneously inhibiting both SRC and EGFR with FDA-approved, CNS permeant inhibitors reverses this resistance and significantly prolongs survival in ispinesib-treated GBM-bearing mice. Furthermore, we find that resistance to several other mitotic inhibitors also utilizes this STAT3-driven mechanism and can likewise be reversed with combined EGFR and SRC inhibition. Thus, our work demonstrates how a promising therapeutic approach, which has been disappointing in GBM, can in fact be rendered effective by anticipating and prospectively treating ab initio the mechanism that drives treatment resistance.
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022
Mehren, Margaret von , Riedel, Richard F. , Agulnik, Mark , Carr, Janai R. , Connelly, Mary, Ganjoo, Kristen N. , Holder, Ashley M. , Homsi, Jade , Keedy, Vicki L. , Kelly, Ciara M. , Kim, Edward , McCarter, Martin D. , McGarry, Sean V., Mesko, Nathan W. , Meyer, Christian F. , Pappo, Alberto S. , Petersen, Ivy A. , Poppe, Matthew M. , Schuetze, Scott M. , Shabason, Jacob E. , Zimel, Melissa N. , Bergman, Mary Anne, Sundar, Hema, Hang, Lisa E., Riedel, Richard F , von Mehren, Margaret , Kane, John M., Sicklick, Jason Keith , Pollack, Seth M. , Bui, Marilyn M. , Choy, Edwin , Connelly, Mary, Dry, Sarah , González, Ricardo , Liebner, David A. , Parkes, Amanda , Spraker, Matthew B.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 9, 2022 | Volume: 20 | Issue: 11 | Pages: 1204-1214

10.6004/jnccn.2022.0058 | PMID 36351335 Get It

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.